WO1999006397A3 - Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists - Google Patents
Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists Download PDFInfo
- Publication number
- WO1999006397A3 WO1999006397A3 PCT/US1998/015479 US9815479W WO9906397A3 WO 1999006397 A3 WO1999006397 A3 WO 1999006397A3 US 9815479 W US9815479 W US 9815479W WO 9906397 A3 WO9906397 A3 WO 9906397A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrrolidine
- carboxylic acid
- acid derivatives
- endothelin antagonists
- endothelin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SK145-2000A SK1452000A3 (en) | 1997-08-04 | 1998-07-27 | Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists |
NZ502395A NZ502395A (en) | 1997-08-04 | 1998-07-27 | 4-Benzodioxolyl substituted pyrrolidine-3-carboxylic acid derivatives useful as endothelin antagonists |
IL13417598A IL134175A0 (en) | 1997-08-04 | 1998-07-27 | Endothelin antagonists |
CA002297894A CA2297894A1 (en) | 1997-08-04 | 1998-07-27 | Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists |
PL98342500A PL342500A1 (en) | 1997-08-04 | 1998-07-27 | Derivatives of pyrolydin-3-carboxylic acid and their application as endothelin antagonists |
AU85921/98A AU748469B2 (en) | 1996-02-13 | 1998-07-27 | Endothelin antagonists |
EP98937139A EP1003740A2 (en) | 1997-08-04 | 1998-07-27 | Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagoists |
JP2000505155A JP2001512119A (en) | 1997-08-04 | 1998-07-27 | Endothelin antagonist |
BR9815296-3A BR9815296A (en) | 1997-08-04 | 1998-07-27 | Derivatives of 3-pyrrolidine carboxylic acid and use of them as endothelin antagonists |
HU0003484A HUP0003484A3 (en) | 1997-08-04 | 1998-07-27 | Pyrrolidine-3-crboxylic acid derivatives and their use as endothelin antagonists |
NO20000542A NO20000542L (en) | 1997-08-04 | 2000-02-02 | Endothelin antagonists |
BG104216A BG104216A (en) | 1997-08-04 | 2000-03-02 | Derivatives of pyrrolidine-3-carbonic acids and their application as endotheline antagonists |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/905,913 US6162927A (en) | 1994-08-19 | 1997-08-04 | Endothelin antagonists |
US4895598A | 1998-03-27 | 1998-03-27 | |
US09/048,955 | 1998-03-27 | ||
US08/905,913 | 1998-03-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999006397A2 WO1999006397A2 (en) | 1999-02-11 |
WO1999006397A3 true WO1999006397A3 (en) | 1999-12-09 |
Family
ID=26726720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/015479 WO1999006397A2 (en) | 1996-02-13 | 1998-07-27 | Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1003740A2 (en) |
JP (1) | JP2001512119A (en) |
CN (1) | CN1301264A (en) |
AU (1) | AU748469B2 (en) |
BG (1) | BG104216A (en) |
BR (1) | BR9815296A (en) |
CA (1) | CA2297894A1 (en) |
HU (1) | HUP0003484A3 (en) |
IL (1) | IL134175A0 (en) |
NO (1) | NO20000542L (en) |
NZ (1) | NZ502395A (en) |
PL (1) | PL342500A1 (en) |
SK (1) | SK1452000A3 (en) |
TR (4) | TR200501137T2 (en) |
TW (1) | TW552260B (en) |
WO (1) | WO1999006397A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2337230A1 (en) * | 1998-07-15 | 2000-01-27 | Bristol-Myers Squibb Company | Stereoselective reductive amination of ketones |
TWI306760B (en) | 2000-08-07 | 2009-03-01 | Abbott Lab | Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same |
WO2002051836A1 (en) * | 2000-12-27 | 2002-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
CN1514727A (en) * | 2001-04-11 | 2004-07-21 | ���Ͽع�����˾ | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to progression of disease in patients with prostate cancer |
FR2874015B1 (en) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | N- (1H-INDOLYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2880625B1 (en) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | N- (HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
WO2007034406A1 (en) * | 2005-09-22 | 2007-03-29 | Actelion Pharmaceuticals Ltd | Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin |
CA2904447C (en) | 2007-08-22 | 2017-01-03 | Abbvie Deutschland Gmbh & Co Kg | Therapy for complications of diabetes |
WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
JO2998B1 (en) | 2010-06-04 | 2016-09-05 | Amgen Inc | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer |
JP6093770B2 (en) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
CA2902856C (en) | 2013-02-28 | 2021-02-16 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
CA2906538C (en) | 2013-03-14 | 2021-02-02 | Ana Gonzalez Buenrostro | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
JOP20200296A1 (en) | 2013-06-10 | 2017-06-16 | Amgen Inc | Processes of Making and Crystalline Forms of a MDM2 Inhibitor |
CN104262329A (en) * | 2014-10-22 | 2015-01-07 | 南京友杰医药科技有限公司 | Preparation method for anti-form atrasentan |
WO2024022262A1 (en) * | 2022-07-25 | 2024-02-01 | 深圳信立泰药业股份有限公司 | Salt of endothelin a (eta) receptor antagonist compound, and preparation method therefor and medical use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0439444A2 (en) * | 1990-01-22 | 1991-07-31 | Monsanto Company | Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors |
WO1996006095A1 (en) * | 1994-08-19 | 1996-02-29 | Abbott Laboratories | Endothelin antagonists |
WO1997030046A1 (en) * | 1996-02-13 | 1997-08-21 | Abbott Laboratories | 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists |
US5668164A (en) * | 1996-07-12 | 1997-09-16 | Abbott Laboratories | Process for synthesis of chiral cis-and trans-3-amino-4 substituted pyrrolidine compounds |
-
1998
- 1998-07-27 IL IL13417598A patent/IL134175A0/en unknown
- 1998-07-27 BR BR9815296-3A patent/BR9815296A/en not_active Application Discontinuation
- 1998-07-27 TR TR2005/01137T patent/TR200501137T2/en unknown
- 1998-07-27 TR TR2001/01233T patent/TR200101233T2/en unknown
- 1998-07-27 CN CN98809462A patent/CN1301264A/en active Pending
- 1998-07-27 PL PL98342500A patent/PL342500A1/en not_active Application Discontinuation
- 1998-07-27 NZ NZ502395A patent/NZ502395A/en unknown
- 1998-07-27 JP JP2000505155A patent/JP2001512119A/en active Pending
- 1998-07-27 EP EP98937139A patent/EP1003740A2/en not_active Ceased
- 1998-07-27 WO PCT/US1998/015479 patent/WO1999006397A2/en not_active Application Discontinuation
- 1998-07-27 HU HU0003484A patent/HUP0003484A3/en unknown
- 1998-07-27 SK SK145-2000A patent/SK1452000A3/en unknown
- 1998-07-27 TR TR2000/00993T patent/TR200000993T2/en unknown
- 1998-07-27 CA CA002297894A patent/CA2297894A1/en not_active Abandoned
- 1998-07-27 AU AU85921/98A patent/AU748469B2/en not_active Ceased
- 1998-07-27 TR TR2001/01234T patent/TR200101234T2/en unknown
- 1998-08-10 TW TW087112783A patent/TW552260B/en not_active IP Right Cessation
-
2000
- 2000-02-02 NO NO20000542A patent/NO20000542L/en not_active Application Discontinuation
- 2000-03-02 BG BG104216A patent/BG104216A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0439444A2 (en) * | 1990-01-22 | 1991-07-31 | Monsanto Company | Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors |
WO1996006095A1 (en) * | 1994-08-19 | 1996-02-29 | Abbott Laboratories | Endothelin antagonists |
WO1997030046A1 (en) * | 1996-02-13 | 1997-08-21 | Abbott Laboratories | 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists |
US5668164A (en) * | 1996-07-12 | 1997-09-16 | Abbott Laboratories | Process for synthesis of chiral cis-and trans-3-amino-4 substituted pyrrolidine compounds |
Non-Patent Citations (7)
Title |
---|
A. S. TASKER ET. AL.: "Potent and Selective Non-benzodioxole Containing Endothelin A Receptor Antagonists"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 3, 31 January 1997 (1997-01-31), pages 322 - 30, XP002082166 * |
C. R. CRAIG ET. AL.: "Modern Pharmacology, Third Edition", LITTLE, BROWN AND COMPANY, BOSTON, US, XP002118728 * |
H-S JAE ET. AL.: "Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 2. Sulfonamide based ETA-ETB Mixed Antagonists.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 20, 26 September 1997 (1997-09-26), pages 3217 - 27, XP002082169 * |
J. G. TOPLISS: "Quantitiative Structure-Activity Relationships of Drugs", ACADEMIC PRESS, NEW YORK, US, XP002118726 * |
J. K. SEYDAL ET. AL.: "Chemische Struktur und biologische Aktivität von Wirkstoffen.", 1979, VERLAG CHEMIE, WEINHEIM, DE, XP002118727 * |
M. WINN ET. AL.: "2,4-Diarylpyrrolidine-3-carboxylci Acids- Potent ETA Selective Endothelin Receptor Antagonists. 1. Discovery of A-127722.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 5, 1 March 1996 (1996-03-01), pages 1039 - 48, XP002082167 * |
S. S. BHAGWAT ET. AL.: "Synthesis of Enantiomerically Pure Pyrrolidinones as Endothelin Receptor Antagonists.", TETRAHEDRON LETTERS, vol. 37, no. 27, 1996, pages 4627 - 30, XP002082168 * |
Also Published As
Publication number | Publication date |
---|---|
IL134175A0 (en) | 2001-04-30 |
CA2297894A1 (en) | 1999-02-11 |
CN1301264A (en) | 2001-06-27 |
NZ502395A (en) | 2002-08-28 |
WO1999006397A2 (en) | 1999-02-11 |
HUP0003484A3 (en) | 2002-02-28 |
BG104216A (en) | 2000-12-29 |
TR200000993T2 (en) | 2000-12-21 |
TW552260B (en) | 2003-09-11 |
AU748469B2 (en) | 2002-06-06 |
TR200501137T2 (en) | 2005-12-21 |
HUP0003484A2 (en) | 2002-01-28 |
SK1452000A3 (en) | 2001-05-10 |
NO20000542D0 (en) | 2000-02-02 |
TR200101233T2 (en) | 2002-06-21 |
BR9815296A (en) | 2001-11-20 |
AU8592198A (en) | 1999-02-22 |
PL342500A1 (en) | 2001-06-04 |
EP1003740A2 (en) | 2000-05-31 |
TR200101234T2 (en) | 2002-06-21 |
NO20000542L (en) | 2000-04-04 |
JP2001512119A (en) | 2001-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2195677A1 (en) | Endothelin antagonists | |
WO1999006397A3 (en) | Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists | |
CA2245587A1 (en) | Novel benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists | |
AU2536097A (en) | Para-substituted phenylpropanoic acid derivatives as integrin antagonists | |
AU2323897A (en) | Cyclopropyl alkanoic acid derivatives | |
WO2001047928A3 (en) | Imidazo 1,3,5 triazinones and the use thereof | |
AU2337197A (en) | Cinnamic acid derivatives and their use as integrin antagonists | |
CA2388639A1 (en) | Inhibitors of .alpha.l.beta.2 mediated cell adhesion | |
CA2263913A1 (en) | Substituted 6,6-hetero-bicyclic derivatives | |
WO2000053610A3 (en) | 4-OXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | |
EP0664289A3 (en) | Isoquinolines | |
WO2001096307A3 (en) | Cycloalkyl alkanoic acids as integrin receptor antagonists | |
WO2001010816A3 (en) | Substituted 2-dialkylaminoalkylbiphenyl derivatives | |
CA2383351A1 (en) | Xanthine derivatives as selective antagonists of a2b adenosine receptors | |
HUP0101766A3 (en) | Processes for producing 7-isoindolinequinolonecarboxylic derivatives and intermediates therefor, salts of 7-isoindolinequinolonecarboxylic acids, hydrates thereof, and composition containing the same as active ingredient | |
WO1999026932A8 (en) | By amidino group substituted heterocyclic derivatives and their use as anticoagulants | |
WO1998027930A3 (en) | New use of aminopiperazine derivatives | |
AU5727899A (en) | Diaminocyclobutene-3,4-dione derivatives, their preparation and use | |
AU4600200A (en) | Salts of 2,2-dimethyl-1,3-dioxane intermediates and process for the preparation thereof | |
CA2256007A1 (en) | Substituted heterocyclic benzocycloalkenes and their use as analgesic | |
AU5428700A (en) | Acrylic acid derivatives, use of the same and intermediates for the preparation thereof | |
NO996244L (en) | Pyrrolidinecarboxylic acid derivatives as endothelin antagonists | |
CA2215333A1 (en) | Heterocyclic substituted piperazinone derivatives as tachykinin receptor antagonists | |
HK1041000B (en) | Novel pyrimidine derivatives and processes for the preparation thereof | |
AU7958000A (en) | Process for the preparation of oxyiminoalkanoic acid derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 134175 Country of ref document: IL Ref document number: 98809462.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 502395 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2297894 Country of ref document: CA Ref document number: 2297894 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-348 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1452000 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007001234 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/001283 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998937139 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 85921/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000/00993 Country of ref document: TR |
|
WWP | Wipo information: published in national office |
Ref document number: 1998937139 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-348 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007001234 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/01233 Country of ref document: TR Ref document number: 2001/01234 Country of ref document: TR |
|
WWG | Wipo information: grant in national office |
Ref document number: 85921/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/01137 Country of ref document: TR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2000-348 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007001234 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1998937139 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998937139 Country of ref document: EP |